Amgen 2009 Annual Report Download - page 45

Download and view the complete annual report

Please find page 45 of the 2009 Amgen annual report below. You can navigate through the pages in the report by either clicking on the pages listed below, or by using the keyword search tool below to find specific information within the annual report.

Page out of 180

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
  • 31
  • 32
  • 33
  • 34
  • 35
  • 36
  • 37
  • 38
  • 39
  • 40
  • 41
  • 42
  • 43
  • 44
  • 45
  • 46
  • 47
  • 48
  • 49
  • 50
  • 51
  • 52
  • 53
  • 54
  • 55
  • 56
  • 57
  • 58
  • 59
  • 60
  • 61
  • 62
  • 63
  • 64
  • 65
  • 66
  • 67
  • 68
  • 69
  • 70
  • 71
  • 72
  • 73
  • 74
  • 75
  • 76
  • 77
  • 78
  • 79
  • 80
  • 81
  • 82
  • 83
  • 84
  • 85
  • 86
  • 87
  • 88
  • 89
  • 90
  • 91
  • 92
  • 93
  • 94
  • 95
  • 96
  • 97
  • 98
  • 99
  • 100
  • 101
  • 102
  • 103
  • 104
  • 105
  • 106
  • 107
  • 108
  • 109
  • 110
  • 111
  • 112
  • 113
  • 114
  • 115
  • 116
  • 117
  • 118
  • 119
  • 120
  • 121
  • 122
  • 123
  • 124
  • 125
  • 126
  • 127
  • 128
  • 129
  • 130
  • 131
  • 132
  • 133
  • 134
  • 135
  • 136
  • 137
  • 138
  • 139
  • 140
  • 141
  • 142
  • 143
  • 144
  • 145
  • 146
  • 147
  • 148
  • 149
  • 150
  • 151
  • 152
  • 153
  • 154
  • 155
  • 156
  • 157
  • 158
  • 159
  • 160
  • 161
  • 162
  • 163
  • 164
  • 165
  • 166
  • 167
  • 168
  • 169
  • 170
  • 171
  • 172
  • 173
  • 174
  • 175
  • 176
  • 177
  • 178
  • 179
  • 180

The following text provides additional information about selected product candidates that have advanced in-
to human clinical trials.
AMG 102
AMG 102 is a fully human monoclonal antibody that blocks the action of hepatocyte growth factor/scatter
factor. It is being investigated as a cancer treatment.
Phase 2 studies of single agent AMG 102 for renal cell carcinoma (“RCC”) and glioblastoma multiforme
(“GBM”) were completed in 2009. Limited efficacy was seen in GBM and RCC when AMG 102 was ad-
ministered in monotherapy, and the effect size was not large enough to warrant moving forward with late-stage
studies in these monotherapy indications.
Phase 2 combination studies with AMG 102 in the gastric, prostate, mCRC and small cell lung cancer set-
tings continue. We expect data from the phase 2 study in mCRC to be available in 2010.
AMG 108
AMG 108 is a fully human monoclonal antibody that targets inhibition of the action of interleukin-1
(“IL-1”).
AMG 222
AMG 222 is an orally-administered small molecule antagonist of DPP-IV. It is being investigated as a treat-
ment of type 2 diabetes. AMG 222 is being developed in partnership with Servier.
In July 2009, we received results from a phase 2a study of AMG 222 in patients with type 2 diabetes. The
results support continued phase 2 development of AMG 222.
AMG 223
AMG 223 is an orally-administered polymer which binds phosphate. It is being investigated as a treatment
of hyperphosphatemia in CKD patients on hemodialysis.
AMG 386
AMG 386 is a peptibody that binds to and inhibits angiopoietin 1 and 2. It is being investigated as a cancer
treatment.
In 2007 and 2008, we initiated five randomized phase 2 studies of AMG 386 for the treatment of RCC,
metastatic breast cancer, ovarian cancer, gastric cancer and colorectal cancer, and numerous other supportive
studies. Based on study results, we plan to initiate a phase 3 trial in ovarian cancer. We expect the results from
these other randomized phase 2 studies to be available in 2010 and 2011.
AMG 479
AMG 479 is a fully human monoclonal antibody antagonist of IGF-1 receptor. It is being investigated as a
cancer treatment.
In 2007, we initiated a phase 2 study of AMG 479 as a potential cancer therapeutic in Ewing’s sarcoma. We
also initiated, in 2008, phase 2 studies for the treatment of advanced breast, pancreatic, colorectal and small cell
lung cancers. We received the results from the phase 2 pancreatic cancer study in the second half of 2009 and we
plan to present the results at an upcoming medical meeting. We expect the results from the phase 2 Ewing’s
sarcoma, metastatic breast cancer and mCRC studies to be available in 2010.
AMG 785
AMG 785 is a humanized monoclonal antibody that targets sclerostin, a protein secreted by bone cells that
inhibits bone formation. AMG 785 (also known as CDP7851) is being developed in collaboration with UCB for
bone-related conditions, including PMO and fracture healing.
33